OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Mazzoni on the Use of Quadruplet Regimens in Newly Diagnosed Myeloma

October 23rd 2024

Sandra Mazzoni, DO, discusses the emerging role of quadruplet regimens in newly diagnosed multiple myeloma.

Dr Dhakal on the Design of the CARTITUDE-4 Study in R/R Myeloma

October 23rd 2024

Binod Dhakal, MD, discusses the design of the CARTITUDE-4 study investigating cilta-cel in relapsed/refractory multiple myeloma.

Dr Cortes on the Phase 4 BYOND Study in Previously Treated Patients With CML

October 21st 2024

Jorge E. Cortes, MD, discusses efficacy and safety findings from the phase 4 BYOND study in previously treated patients with Ph+ chronic myeloid leukemia.

Dr Girard on Findings From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC

October 21st 2024

Nicolas Girard, MD, discusses finding from the LUMINOSITY trial in c-Met protein–overexpressing, EGFR wild-type, non–small cell lung cancer.

Dr Adige on Improving QOL Post–Breast Cancer Treatment

October 21st 2024

Sunil Adige, MD, discusses aspects of post-treatment care that can improve long-term quality of life and reduce the risk of breast cancer recurrence.

Dr Battiwalla on the Potential Roles of FLT3-ITD and Menin Inhibitors in AML Management

October 21st 2024

Minoo Battiwalla, MD, MS, discusses the potential of FLT3-ITD and menin inhibitors to broaden the acute myeloid leukemia treatment paradigm.

Dr Klempner on the FDA Approval of Zolbetuximab for CLDN18.2+, HER2– Gastric or GEJ Adenocarcinoma

October 18th 2024

Samuel J. Klempner, MD, discusses the FDA approval of zolbetuximab for CLDN18.2+, HER2–, locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma.

Dr Corre on the Clinical Implications of D-VTd Treatment in Newly Diagnosed Myeloma

October 18th 2024

Jill Corre, PharmD, PhD, discusses the implications of using daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.

Dr Tang on Unanswered Questions About the Role of Radiation Therapy in RCC

October 18th 2024

Chad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.

Dr Nowakowski on the Significance of the TakeAim Lymphoma Trial in PCNSL

October 17th 2024

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.

Dr Gordon on Next Steps for Optimizing Liso-Cel Use in R/R MCL

October 17th 2024

Leo I. Gordon, MD, discusses future steps for optimizing the use of lisocabtagene maraleucel in the treatment of relapsed/refractory mantle cell lymphoma.

Dr Friedlander on Emerging Agents of Interest in Urothelial Cancer

October 17th 2024

Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.

Dr Nowakowski on the Implications of the FDA Approval of Epcoritamab in Follicular Lymphoma

October 17th 2024

Grzegorz S. Nowakowski, MD, discusses the clinical implications of the FDA approval of third-line epcoritamab for relapsed/refractory follicular lymphoma.

Dr Corre on the Rationale for the CASSIOPEIA Trial in Newly Diagnosed Myeloma

October 17th 2024

Jill Corre, PharmD, PhD, discusses the CASSIOPEIA trial of daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.

Dr Amanam on Currently Available JAK Inhibitors for Myelofibrosis

October 17th 2024

Idoroenyi Amanam, MD, discusses the JAK inhibitors he most commonly reaches for in his clinical practice when treating patients with myelofibrosis.

Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive Myelofibrosis

October 16th 2024

Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.

Dr Klisovic on a Case Discussion of Momelotinib in Myelofibrosis With Anemia

October 16th 2024

Rebecca Klisovic, MD, discusses 3 case studies about patients with myelofibrosis.

Dr Lorusso on Key Takeaways About Relacorilant Combination Treatment in Ovarian Cancer

October 16th 2024

Domenica Lorusso, MD, PhD, discusses the selective glucocorticoid receptor modulator relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Dr Lin on the Importance of the DESTINY-Breast12 Trial for T-DXd Use in HER2+ Breast Cancer With Brain Metastases

October 16th 2024

Nancy U. Lin, MD, discusses the importance of the DESTINY-Breast12 trial of T-DXd in patients with HER2+ breast cancer with vs without brain metastases.

Dr Lee on the Significance of the Tumor-Agnostic Approval of T-DXd for HER2+ Urothelial Cancer

October 16th 2024

John K. Lee, MD, PhD, discusses the significance of the tumor-agnostic approval of T-DXd specifically for patients with HER2-positive urothelial cancer.